Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage
Compositions and methods reduce and penetrate biofilms and mucus barriers to deliver pyruvate that increases synthesis of nitric oxide inhibiting replication and severity of bacterial, virus and fungal infections in lungs or nasal cavity, increase lung functions and reduce coughing reflex by reducing inflammatory cytokines that stimulate Vagus nerve coughing reflex and to eliminate bacterial toxins that cause brain diseases like Alzheimer's, and Parkinson's. It reduces symptoms, including hypoxemia, cytokine storm and lung fibrosis when biofilms are destroyed. Composition is sodium pyruvate; sodium chloride; benzalkonium chloride; alcohol selected from: ethanol, isopropanol, methyl alcohol or phenylethyl alcohol; and an aqueous carrier.
1 . A composition useful for delivering sodium pyruvate and other drugs through biofilms and mucus barriers to stimulate and increase the synthesis of nasal nitric oxide, that will reduce viral and bacterial replication, duration, spread and counts to reduce the severity of infections, to increase lung and sinus functions, reduce coughing, sneezing, inflammatory cytokines and toxins that effect the Vagus nerve, caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, long COVID, interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, rhinitis medicamentosa also known as rebound rhinitis, allergic rhinitis, congestion, rebound effects of oxymetazoline, seasonal allergies, sinusitis, with migraines, Alzheimer's, Parkinsons and pulmonary hypertension which comprises the following constituents:
a) sodium pyruvate;
b) sodium chloride;
c) benzalkonium chloride;
d) an alcohol selected from: ethanol, isopropanol, methyl alcohol or phenylethyl alcohol; and,
e) an aqueous carrier;
wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01% to 1%, sodium chloride ranges from 0.45% to 0.93%;
benzalkonium chloride ranges from 0.01% to about 0.2% and alcohol ranges from 0.01% to about 0.2%, balance is said aqueous carrier, all percentages by weight.
2 . The composition of claim 1 wherein said sodium chloride ranges from 0.6% to 0.93% by weight, and is in a saline solution with said aqueous carrier.
3 . The composition of claim 1 wherein said benzalkonium chloride ranges from 0.04% to about 0.1% and alcohol ranges from 0.04% to about 0.1%, by weight.
4 . The composition of claim 1 wherein said benzalkonium chloride content is about 0.06% and said alcohol content is about 0.06%, by weight.
5 . The composition of claim 1 wherein said alcohol is ethanol.
6 . The composition of claim 1 wherein said alcohol is isopropanol.
7 . The composition of claim 1 wherein said alcohol is selected from the group consisting of ethanol, isopropanol, and combinations thereof.
8 . The composition of claim 1 wherein said aqueous carrier is water selected from the group consisting of purified water and distilled water.
9 . The composition of claim 1 wherein said composition contains the following amounts of said constituents: sodium chloride at about 0.9%; sodium pyruvate at about 0.21%, benzalkonium chloride at about 0.06% and alcohol at about 0.06%, all by weight.
10 . A method for delivering sodium pyruvate and other drugs through biofilms and mucus barriers to stimulate and increase the synthesis of nasal nitric oxide, that will reduce viral and bacterial replication, duration, spread and counts to reduce the severity of infections, to increase lung and sinus functions, reduce coughing, sneezing, inflammatory cytokines and toxins that effect the Vagus nerve, caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, long COVID, interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, rhinitis medicamentosa also known as rebound rhinitis, allergic rhinitis, congestion, rebound effects of oxymetazoline, seasonal allergies, sinusitis, with migraines, Alzheimer's, Parkinsons and pulmonary hypertension which comprises:
contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:
a) sodium pyruvate;
b) sodium chloride;
c) benzalkonium chloride;
d) an alcohol selected from: ethanol, isopropanol, methyl alcohol or phenylethyl alcohol; and,
e) an aqueous carrier;
wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01% to 1%, sodium chloride ranges from 0.45% to 0.93%; benzalkonium chloride ranges from 0.01% to about 0.2% and alcohol ranges from 0.01% to about 0.2%, balance is said aqueous carrier, all percentages by weight.
11 . The method of claim 10 wherein said sodium chloride ranges from 0.6% to 0.93% by weight, and is in a saline solution with said aqueous carrier.
12 . The method of claim 10 wherein said benzalkonium chloride ranges from 0.04% to about 0.1% and alcohol ranges from 0.04% to about 0.1%, by weight.
13 . The composition of claim 1 wherein said benzalkonium chloride content is about 0.06% and said alcohol content is about 0.06%, by weight.
14 . The method of claim 10 wherein said composition contains the following amounts of said constituents: sodium chloride at about 0.9%; sodium pyruvate at about 0.21%, benzalkonium chloride at about 0.06% and alcohol at about 0.06%, all by weight.
15 . The method of claim 10 wherein said method includes a step using an enhancing composition to enhance the efficacy of pulmonary drugs, steroids and cancer medications, where the enhancing composition is administered before and after said treatment that includes the composition set forth in the method of claim 10 .
16 . The method of claim 10 wherein said alcohol is ethanol and wherein said aqueous carrier is water selected from the group consisting of purified water and distilled water.
17 . A method for delivering sodium pyruvate and other drugs through biofilms and mucus barriers to stimulate and increase the synthesis of nasal nitric oxide, that will reduce viral and bacterial replication, duration, spread and counts to reduce the severity of infections, to increase lung and sinus functions, reduce coughing, sneezing, inflammatory cytokines and toxins that effect the Vagus nerve, caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, long COVID, interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, rhinitis medicamentosa also known as rebound rhinitis, allergic rhinitis, congestion, rebound effects of oxymetazoline, seasonal allergies, sinusitis, with migraines, Alzheimer's, Parkinsons and pulmonary hypertension which comprises:
contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:
f) sodium pyruvate;
g) sodium chloride;
h) benzalkonium chloride;
i) an alcohol selected from: ethanol, isopropanol, methyl alcohol or phenylethyl alcohol; and,
j) an aqueous carrier;
wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01% to 1%, sodium chloride ranges from 0.45% to 0.93%; benzalkonium chloride ranges from 0.01% to about 0.2% and alcohol ranges from 0.01% to about 0.2%, balance is said aqueous carrier, all percentages by weight; and,
wherein a therapeutic agent is administered relative to contacting said mammalian cells with said composition, and said therapeutic agent is administered at a time selected from the group consisting of: prior to, simultaneously with, and after, contacting said mammalian cells with said composition.
18 . The method of claim 17 wherein said sodium chloride ranges from 0.6% to 0.93% by weight, and is in a saline solution with said aqueous carrier.
19 . The method of claim 17 wherein said sodium chloride ranges from 0.6% to 0.93% by weight, and is in a saline solution with said aqueous carrier and wherein said aqueous carrier is water selected from the group consisting of purified water and distilled water.
20 . The method of claim 17 wherein said benzalkonium chloride ranges from 0.04% to about 0.1% and alcohol ranges from 0.04% to about 0.1%, by weight.